The use of 0.5 mg/0.05 ml of ranibizumab intracamerally, to induce regression of iris neovascularisation in a non-diabetic patient, is reported. A 55-year-old Malay man presented with left eye rubeosis and hyphaema secondary to ischaemic remnant retinal flap in his silicone filled pseudophakic eye. Regression of rubeosis and resolution of hyphaema was noted within 4 days of injection of intracameral ranibizumab, allowing repeat vitrectomy to be performed without much bleeding, thus facilitating removal of his intraocular lens and laser to remaining flap. One month postoperatively he remained comfortable with counting fingers vision similar to the pre-hyphaema period.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3029625PMC
http://dx.doi.org/10.1136/bcr.10.2009.2398DOI Listing

Publication Analysis

Top Keywords

regression iris
8
iris neovascularisation
8
non-diabetic patient
8
ischaemic remnant
8
remnant retinal
8
retinal flap
8
flap silicone
8
silicone filled
8
intracameral injection
4
injection ranibizumab
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!